GSK2982772 is a highly selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) being developed to treat chronic inflammatory diseases. This first-in-human study evaluated safety, tolerability, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) of GSK2982772 administered orally to healthy male volunteers. This was a Phase I, randomized, placebo-controlled, double-blind study. In Part A, subjects received were contact dermatitis and headache. Most AEs were mild in intensity, and there were no deaths or serious AEs. The PK of GSK2982772 was approximately linear over the dose range studied (up to 120 mg BID). There was no evidence of drug accumulation upon repeat dosing. Greater than 90% RIPK1 TE was achieved over a 24-hour period for the 60-mg and 120-mg BID dosing regimens. Single and repeat doses of GSK2982772 were safe and well tolerated. PK profiles showed dose linearity. The high levels of RIPK1 TE support progression into Phase II clinical trials for further clinical development.
| INTRODUCTION
Necroptosis, or programmed necrosis, is a form of cell death that causes inflammation by damaging cell function and/or releasing damage-associated molecular patterns. 1 Emerging evidence indicates that necroptosis may play a critical role in mediating a variety of human disease pathologies, including ischemia-reperfusion injury, pancreatitis, myocardial infarction, atherosclerosis, liver disease, neurodegenerative disorders, and immune-mediated inflammatory diseases such as inflammatory bowel diseases, rheumatoid arthritis, and psoriasis. 2, 3 Small-molecule inhibitors of necroptosis are currently being developed as a new class of anti-inflammatory agents with broad therapeutic potential. 3 Receptor-interacting protein kinase 1 (RIPK1) has emerged as an important therapeutic target for small-molecule kinase inhibitors because of its central role in mediating necroptosis in response to a variety of upstream activators, including the signaling that follows engagement of the tumor necrosis factor (TNF) receptor 1. 4 In addition to regulating necroptosis, RIPK1 can also activate inflammatory apoptotic cell death and proinflammatory cytokine production, highlighting its central role in promoting cell damage and inflammation. 4 Moreover, inhibition of RIPK1 kinase activity by small-molecule inhibitors or by targeted disruption of RIPK1 enzymatic activity protects against cellular damage and prevents inflammation in numerous animal models of human disease pathologies. 2 A number of other reported RIPK1 kinase inhibitors have been developed and used in preclinical models, including the necrostatin series. 5 However, moderate potency and poor developability properties for this series, including the leading exemplar Nec-1, appear to have precluded further clinical development.
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GSK2982772 is the first oral, monoselective, small-molecule inhibitor of RIPK1 and necroptosis to advance into human clinical studies. GSK2982772 binds in an allosteric pocket of the RIPK1 kinase domain and is a potent inhibitor of RIPK1-mediated cell death and cytokine production in preclinical models. The objective of this firstin-human study was to evaluate the safety, tolerability, pharmacokinetics (PK), exploratory target engagement, and pharmacodynamics (PD) of single and repeat doses of GSK2982772 in healthy male volunteers in order to support future clinical development in chronic inflammatory diseases. Additional exclusion criteria that were applied only in Part B of the study included cholesterol levels ≥300 gm/dL or triglyceride levels ≥250 mg/dL, significant risk or history of suicidality and positive antinuclear antibody (ANA) results outside of the normal reference range.
| MATERIALS AND METHODS

| Participants
The "all screened subjects" population was defined as all subjects who were screened for eligibility. The "all subjects" population was defined as all subjects who received at least 1 dose of study medication. The "PK population" was defined as subjects in the "all subjects" population for whom at least 1 PK sample was obtained and analyzed.
| Permitted/prohibited drugs
Subjects were prohibited from taking any prescription or nonprescription drugs, including vitamins and dietary or herbal supplements, prior to the first dose of study medication until completion of the follow-up visit, unless the investigator and sponsor judged that the medication would not interfere with the study drug. However, paracetamol/acetaminophen at doses of ≤2 g/day was permitted for use any time during the study. Other concomitant medications were considered on an individual basis. 
| Study design
| Endpoints
The primary endpoint was the safety and tolerability of GSK2982772 as determined by the rates of adverse events (AEs) 
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Pbo The plasma 4b-hydroxycholesterol-to-cholesterol ratio pretreatment and following repeat dosing of GSK2982772 was used as a marker to evaluate the potential of GSK2982772 to induce cytochrome P450 (CYP3A4). 7 In addition, the ex vivo GSK2982772
blood to plasma concentration ratio over a range of concentrations and percent blood cell association was assessed.
Exploratory PD endpoints were measured in Parts A and B, which included determining the level of RIPK1 target engagement (TE) and levels of macrophage inflammatory protein (MIP)-1a and MIP-1b after TNF pathway activation in whole blood samples. 8 These cytokines are produced in a RIPK1-dependent fashion following ex vivo stimulation.
| PK methods
PK parameters from Parts A and B were planned to be derived based on GSK2982772 concentrations obtained in blood to compare safety margins vs the nonclinical safety studies. In Part A, only whole blood samples were collected for PK analysis; in Part B, both blood and plasma samples were processed for PK analysis; and in Part C, only plasma samples were processed for PK analysis.
Blood samples were collected into ethylenediaminetetraacetic acid (EDTA) tubes using venipuncture technique for PK analysis and metabolite identification. Samples for blood assay were diluted with an equal volume (1:1) of deionized water. The plasma samples were processed by centrifugation at 1500 g for 10 minutes at 2-8°C. Both blood and plasma samples were analyzed for GSK2982772 concentrations using a validated analytical method based on protein precipitation, followed by high-performance liquid chromatography-tandem mass spectrometry analysis. The lower limit of quantitation was 0.2 ng/mL and the upper limit of quantitation was 100 ng/mL.
PK parameters were determined from the blood/plasma GSK2982772 concentration-time data using a standard noncompartmental analysis in Phoenix WinNonlin Version 6.4 (Certara, Princeton, NJ, USA) using actual blood sampling times. Accumulation ratios were determined where applicable using mixed effects models.
| Analysis of metabolism
Residual blood/water and plasma PK samples, urine samples, and bile samples were analyzed for relative levels of GSK2982772 and any metabolites as part of a separate study. Urine samples were collected at various time points. Bile samples were collected via an Entero-Test 9 from 1 cohort in Part B on Days À1 and 7 based on emerging safety and PK data during the study. The Entero-Test was administered approximately 2 hours following the subjects' morning GSK2982772 dose administration.
| PD and biomarker assessment
Plasma samples collected pretreatment and at the end of repeat dosing in Part B were analyzed for 4b-hydroxycholesterol and cholesterol levels using a validated liquid chromatography-mass spectrometry method. In Part B Cohorts 3, 4, and 5, the ratio of 4b-hydroxycholesterol to cholesterol was compared between baseline and Day 14, and for Part B Cohort 6, the comparison was made between baseline and Day 15.
The PD response in blood was assessed using an ex vivo challenge assay to assess RIPK1 activity-dependent signaling. Preclinical validation studies identified MIP-1a and MIP-1b, proinflammatory cysteine-cysteine family chemokines, as suitable analytes. 10 These cytokine levels were analyzed following ex vivo stimulation of cells with a stimulation cocktail in TruCulture (Myriad RBM, Austin, TX, USA) tubes (unpublished data on file, GlaxoSmithKline, Collegeville, PA). Whole blood (1 mL) was drawn into TruCulture tubes containing 2 mL of stimulation cocktail (medium containing TNF, zVAD, and SMAC mimetic) and incubated for 6 hours at 37°C. 8, 11 The assay was optimized in preclinical studies by pretreating whole blood with GSK2982772 for 1 hour and then transferring 1 mL of the treated blood to TruCulture tubes containing stimulation cocktail in 2 mL of media. Plasma was separated and concentrations of MIP-1a and MIP-1b were quantified using the Meso Scale Discovery platform (Meso Scale Diagnostics, Rockville, MD, USA).
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RIPK1 TE by GSK2982772 in the blood was assessed using a novel immunoassay, which detects a conformational change induced by inhibitor binding. The percent (%) TE was calculated based on the ratio of the signals from 2 antibodies that differentially bind "drugbound" vs "unbound" RIPK1 protein (unpublished data on file, GlaxoSmithKline, Collegeville, PA). Two parallel sets of samples were evaluated. Initially, TE was assessed in the PD samples using the cellular fraction recovered from the TruCulture tubes. A secondary post hoc analysis was performed using a parallel set of unstimulated blood samples obtained at the same time as the PD samples. Lysates were prepared from both sets of blood samples, and TE was evaluated using identical assay conditions.
| Statistical analysis
PK parameters for Parts A, B, and C were summarized by treatment using descriptive statistics. C max between the tablet and capsule formulations were assessed using mixed effects models and by nonparametric methods for t max . 12 The percentages of inhibition of MIP-1a and MIP-1b were assessed from the analysis of change from baseline using a log e transformation using a mixed effects repeated measures analysis adjusted for baseline concentrations. TE using the difference in log etransformed free TE assay for RIPK1 (TEAR) and log e -transformed total TEAR1 was assessed using a mixed effects repeated measures analysis adjusted for baseline-free and total TEAR1.
3 | RESULTS
| Demographics
A total of 79 subjects were enrolled in the study (19 in Part A, 48 in Part B, and 12 in Part C). Subject demographics are described in Table 1 . In Part A, 4 of the 19 randomized subjects withdrew from the study, 3 of whom were replaced by other subjects during subsequent crossover periods. Of the 4 subjects who withdrew, 1 subject in Cohort 1 withdrew after Period 1 due to investigator discretion.
Three subjects in Cohort 2 withdrew due to investigator discretion (Period 1), diagnosis of herpes zoster 27 days after placebo treatment and 42 days after the last dose of GSK2982772 (80 mg) (Period 2) and personal reasons (Period 3), respectively. There were no withdrawals among the 48 subjects in Part B, and only 1 of 12 subjects withdrew from Part C due to investigator discretion.
| Adverse events
In Part A, 14 of 19 subjects reported AEs. The most commonly reported AEs were contact dermatitis (n = 5) followed by headache (n = 3), nasopharyngitis (n = 2), and abnormal dreams (n = 2). All AEs were of mild intensity except for neck pain and fatigue in 1 subject each, which were of moderate intensity. AEs were not dose dependent (data not shown). The overall relative risk ratio for contact dermatitis and headache was approximately 2, which shows that GSK2982772 treatment increases the risk of this event when compared with placebo, although both CIs contained 1.
In Part B, the most common AEs were contact dermatitis and headache (Table 2) . No dose-dependent effect was observed. Most
AEs were of mild intensity; AEs of moderate intensity included headache in 2 subjects (1 treated with placebo and 1 with GSK2982772 60 mg BID), nasopharyngitis in 1 subject (GSK2982772 120 mg BID), a ligament sprain in 1 subject (GSK2982772 60 mg QD), depressed mood in 1 subject (GSK2982772 60 mg BID), and an upper respiratory tract infection in 1 subject (GSK2982772 20 mg QD). The overall relative risk ratio for the events when compared with placebo was 1 for nausea and contact dermatitis, and <1 for rash, nasopharyngitis, medical device site reaction, headache, and fatigue.
A total of 3 drug-related AEs, all of mild intensity, were reported in 2 subjects in Part A. One subject experienced a herpes zoster infection of mild intensity that led to the subject's withdrawal from the study. This occurred in a 36-year-old male, 27 days after placebo treatment and 42 days after last dose of GSK2982772 (80 mg AUC 0-∞ , area under the blood/plasma concentration-time curve from time zero to infinite time; AUC 0-tau , area under the blood/plasma concentrationtime curve from time zero to the time of the last quantifiable concentration; BID, twice daily; C max , maximum blood/plasma concentration; CV, coefficient of variance; PK, pharmacokinetics; QD, once daily; t ½ , terminal elimination half-life; t max , time to reach C max .
| Pharmacokinetics
Issues were identified with the water dilution method process (pipettes were not calibrated) for the whole blood samples. Thus, the accuracy of the reported whole blood concentrations was deemed unreliable. Hence, PK parameters collected during Part A were summarized descriptively without any statistical analysis, and blood to plasma ratios in Part B were not calculated. Under fed conditions, there was a slight lag in time to peak concentration of GSK2982772 resulting in a median t max of 3 hours compared with a median t max of 2 hours in the fasted state. Based on the AUC 0-∞ values, the overall extent of absorption appeared to be similar in the fed and fasted state.
After attainment of C max , blood concentrations declined rapidly until approximately 12 hours postdose with a t ½ of approximately 2-3 hours followed by a slower terminal phase t ½ of approximately 5-6 hours ( Figure 2 ). The majority of systemic exposure was associated with the shorter half-life of 2-3 hours.
| Part B
For Part B, the PK parameters were derived using GSK2982772 plasma concentrations instead of whole blood because of the issues identified with the blood sample preparation in Part A. Table 3 
| Metabolites in blood, urine, and bile
Unchanged GSK2982772 and a metabolite formed by N-glucuronidation were the major circulating drug-related components observed in blood and plasma extracts after both single and repeat oral dosing. In addition, a minor desmethyl metabolite was also present in plasma. The N-glucuronide metabolite was also identified in urine along with trace levels of unchanged GSK2982772. Similarly, GSK2982772 (possibly originating from unabsorbed dose), the Nglucuronide metabolite, and a second isomeric N-glucuronide metabolite were identified in extracts of duodenal bile collected at 6.5 hours on Day 7 after repeat 60-mg BID dosing. is presented in Figure 6 . There was a concentration-dependent relationship between GSK2982772 and MIP-1a with an estimated IC 50 of 1.36 ng/mL (Figure 7) . IC 50 for MIP-1b inhibition was similar to that for MIP-1a (data not shown).
| 4b-Hydroxycholesterol biomarker
No increase in the mean plasma 4b-hydroxycholesterol to cholesterol ratio was detected following repeated dose administration of GSK2982772 at all dosage levels, indicating that there was no evidence of CYP3A4 induction by GSK2982772 following 14 days of dosing.
| DISCUSSION
The majority of the AEs reported were mild in intensity in this firstin-human study of GSK2982772 dosages ranging from a total dose of 0.1-120 mg given QD or BID per day. Neither the frequency nor the intensity of AEs demonstrates a relationship to increasing dose.
The most common AEs were contact dermatitis and headache, which GSK2982772 inhibited RIPK1 activity in blood, in a concentration-dependent manner, as measured by the inhibition of MIP-1a and MIP-1b production in an ex vivo challenge assay. 8 The level of GSK2982772 binding to RIPK1 in blood, measured by the TE assay, exhibited a similar concentration-dependent profile. The concentration of GSK2982772 needed to elicit a half-maximal response in all assays was similar (approximately 1.4 ng/mL). For both the QD and BID dosing regimens, the mean RIPK1 TE was ≥95% at 1.5 hours postdose. The 60-mg and 120-mg BID dosing regimens achieved approximately 90% TE over 24 hours, whereas TE fell to below 40%
by 24 hours postdose for the QD dosing regimen. A limitation of the study included a blood dilution error in Part A of this study, which precluded statistical analyses of the single-dose PK parameters.
Currently, there are 3 ongoing clinical trials to assess the safety, tolerability, and clinical efficacy of GSK2982772 in patients with inflammatory disorders. These include Phase II trials enrolling patients with moderate to severe rheumatoid arthritis (NCT02858492), ulcerative colitis (NCT02903966), or plaque-type psoriasis (NCT02776033).
| CONCLUSION S
Single and repeat doses of GSK2982772 were generally safe and well tolerated in healthy adult male volunteers. The favorable results of this first-in-human study support further development of the drug in a Phase II trial.
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